The study, led by Deming, Toapanta, and Pasetti, marks a significant breakthrough by utilizing a recombinant technology combined with an innovative delivery method. Unlike conventional vaccines administered intramuscularly, this novel candidate is delivered intranasally. This approach is designed to stimulate mucosal immunity directly in the respiratory tract — the primary site of influenza virus entry and replication. By harnessing local immune defense mechanisms, the vaccine may offer superior protection and reduce transmission rates.

Recombinant vaccine technology involves the production of viral antigens using engineered genetic materials in a laboratory setting. This method allows for precise targeting of the hemagglutinin (HA) protein, a critical surface antigen of the influenza virus responsible for host cell attachment. The vaccine in question features a recombinant form of the HA protein from the H5 subtype, expertly engineered to provoke a robust immune response without introducing live virus, thus enhancing safety.

Central to the vaccine’s efficacy is the inclusion of an adjuvant— a compound that boosts the immune system’s response to the antigen. The adjuvant used in this study augments the activation of antigen-presenting cells and promotes the generation of long-lasting memory B and T cells. This ensures that the immune system not only responds vigorously after vaccination but also retains the ability to recognize and combat a wide array of H5N1 viral strains in the future.

The challenge posed by H5N1 lies in its genetic diversity, with multiple clades exhibiting different antigenic profiles. Traditional vaccines often fail to provide cross-protection across these variants. However, the phase I trial results demonstrated that this recombinant vaccine induced immunity capable of priming the immune system broadly, showcasing responses against multiple divergent clades. This cross-clade reactivity is crucial for preempting potential pandemics originating from novel H5N1 strains.

Safety and tolerability are vital milestones in vaccine development, especially with novel formulations and delivery routes. The intranasal vaccine was well-tolerated by trial participants, with no severe adverse events linked to its administration. Mild local symptoms, such as nasal irritation, were transient and resolved without intervention. This safety profile supports further clinical development and underscores the feasibility of intranasal vaccines in humans.

Immunogenicity—the ability of a vaccine to provoke an immune response—was assessed by measuring neutralizing antibody titers and T-cell responses. Participants exhibited significant increases in neutralizing antibodies against diverse H5N1 strains, indicating a strong humoral immune response. Additionally, enhanced T-cell activation was observed, reflecting a comprehensive cellular immune defense. Such dual-arm immunity is critical for both immediate viral neutralization and long-term protection.

The intranasal route offers logistical advantages over intramuscular injections. It facilitates needle-free administration, which can increase vaccine acceptance and coverage, particularly in resource-limited regions and among needle-phobic populations. Furthermore, mucosal immunity has the potential to inhibit viral replication and shedding at the point of entry, thereby decreasing potential transmission—a crucial factor in controlling outbreaks.

Technologically, this vaccine represents the convergence of advanced molecular biology, immunology, and pharmaceutical sciences. Recombinant DNA technology, adjuvant science, and nasal delivery devices have been fine-tuned to orchestrate an optimal immune response. This integration could redefine influenza vaccination paradigms and inspire similar strategies for other respiratory viruses such as SARS-CoV-2 and respiratory syncytial virus.

While the study was limited to phase I—primarily evaluating safety and immunogenicity—its promising results justify progression to larger trials. Subsequent phases will assess efficacy in diverse populations, dosing schedules, and long-term protection. Moreover, understanding the vaccine’s ability to reduce transmission and severe disease in real-world settings will be paramount for its global implementation.

This vaccine’s development arrives at a critical juncture. Influenza remains a persistent threat with seasonal epidemics and pandemic potential always looming. H5N1, in particular, has caused sporadic human infections with high mortality rates. Current vaccine production methods are slow and strain-specific, often lagging behind viral evolution. A fast-acting, broadly protective intranasal vaccine could revolutionize public health responses to influenza outbreaks.

The broader implications of this research extend beyond influenza. Intranasal delivery and recombinant antigen platforms can be adapted rapidly to emerging pathogens, offering a more nimble response to novel infectious threats. The observed cross-clade immunity opens the possibility of universal vaccines that cover multiple variants, reducing the need for annual reformulation and mass vaccination campaigns.

Efforts to scale manufacturing and distribution will be crucial for future success. The vaccine’s recombinant nature facilitates rapid and scalable production in cell cultures, bypassing egg-based containment systems that can delay availability. Coupled with the simplicity of nasal administration, this approach may lower barriers to widespread immunization, especially in low- and middle-income countries where influenza burden is significant.

In summary, the intranasal adjuvanted recombinant H5 vaccine trial represents a pioneering step toward universal influenza vaccination. By effectively priming immunity against diverse clades of H5N1, it addresses key challenges in viral variability and vaccine delivery. If confirmed in later-stage studies, this innovation holds the promise of transforming influenza prevention worldwide and enhancing preparedness for future pandemics.

As this novel vaccine advances through clinical development, the scientific community eagerly anticipates its impact on global influenza control strategies. The integration of advanced biotechnology and mucosal immunology could redefine effective vaccination, protecting millions from seasonal epidemics and pandemic threats. This research underscores the vital role of innovative science in safeguarding public health in an ever-changing viral landscape.

The journey from bench to bedside for this vaccine illustrates the power of interdisciplinary collaboration and cutting-edge technologies. Continued investment in such research is essential to stay ahead in the arms race against evolving infectious diseases. With each milestone, the possibility of a universal, easily administered influenza vaccine becomes more tangible, heralding a new era in disease prevention.

Subject of Research: Development and clinical evaluation of an intranasal adjuvanted recombinant influenza A/H5 vaccine conferring cross-clade immunity against diverse H5N1 strains.

Article Title: An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial.

Article References:
Deming, M.E., Toapanta, F.R., Pasetti, M. et al. An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial. Nat Commun 16, 9321 (2025). https://doi.org/10.1038/s41467-025-64686-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-64686-3

Age-related macular degeneration is a leading cause of vision loss globally, particularly among individuals over 60 years old. The disease affects nearly 200 million people worldwide, manifesting most aggressively in its neovascular or “wet” form. This condition is characterized by the proliferation of aberrant blood vessels in the retina, a process termed pathological neovascularization. These vessels are prone to leakage, leading to retinal edema and hemorrhage, gradually impairing central vision if untreated. Present therapies involve frequent intravitreal administration of anti-angiogenic agents such as VEGF inhibitors, a protocol that imposes a substantial treatment burden on patients.

The Institute of Science Tokyo’s novel approach circumvents the need for direct ocular injections. Instead, the vaccine is delivered intramuscularly, inducing a systemic immune response that targets the pathological drivers of abnormal blood vessel growth. This method not only simplifies administration but potentially enhances patient compliance by eliminating the discomfort and risk associated with intraocular injections. The vaccine induces the production of antibodies against leucine-rich alpha-2-glycoprotein 1 (LRG1), a molecule found to be elevated in AMD patients and implicated in promoting angiogenesis in the eye.

The research, led by Professor Satoshi Uchida and Visiting Professor Yasuo Yanagi, employed two distinct mouse models to assess therapeutic efficacy: one with laser-induced choroidal neovascularization (CNV) and another exhibiting spontaneous CNV development. Following two intramuscular injections spaced 14 days apart, both models exhibited robust antibody generation and significant suppression of abnormal vascular growth. Remarkably, reductions in vascular leakage and lesion size reached over 80% in the induced model and about 55% in the spontaneous model, with visible effects emerging within a week post-initial vaccination.

Mechanistically, the mRNA vaccine utilizes a platform that encodes the LRG1 protein, which instigates the body’s immune system to produce neutralizing antibodies. Unlike traditional vaccines targeting pathogens, this therapeutic vaccine targets a host protein involved in pathological angiogenesis. This strategy effectively disrupts the aberrant signaling pathways that fuel neovascularization in AMD, thereby protecting retinal integrity without impeding normal vascular functions.

Safety evaluations revealed the vaccine did not induce deleterious immune reactions or compromise physiological angiogenesis required for ocular health. Importantly, no adverse effects on adjacent retinal tissues or systemic toxicity were observed in treated animals. The therapeutic outcomes mirrored those seen with standard anti-VEGF therapies, yet the novel intervention holds the promise of reduced treatment frequency and enhanced patient tolerability.

The success of this mRNA vaccine builds upon the transformative potential demonstrated by mRNA vaccines throughout the COVID-19 pandemic. This platform allows rapid development and versatile targeting, ushering in a new era where chronic diseases such as AMD can be addressed through immunization strategies. The vaccine’s systemic administration route signifies a paradigm shift in ocular pharmacotherapy, offering hope for drastically improving quality of life for millions suffering from neovascular eye diseases.

Further research is warranted to evaluate the translational potential of this vaccine in clinical settings. Human trials will be critical to confirm efficacy, dosage optimization, and long-term safety. If successful, this innovation could render the painful, frequent eye injections obsolete and reshape the standard treatment landscape for AMD and related retinal disorders.

The findings were published in the esteemed journal Vaccine in August 2025, underscoring the rapidly expanding horizon of mRNA technology applications. Financial support was provided by the Japan Agency for Medical Research and Development, the Japan Science and Technology Agency, and the Institute of Science Tokyo itself. Patent interests are associated with lead researchers, reflecting the commercial and therapeutic potential of the vaccine.

As global populations age, the burden of vision loss due to AMD continues to rise, imposing significant social and economic costs. Therapeutic strategies that can offer durable, less invasive protection against disease progression are urgently needed. This innovative mRNA vaccine embodies a visionary approach, promising to enhance treatment adherence while delivering efficacious results.

In conclusion, the Institute of Science Tokyo’s mRNA vaccine represents a landmark advancement in neovascular eye disease therapy. By harnessing the precision of genetic immunotherapy, it not only curtails pathological blood vessel growth but does so with a delivery method far less taxing than current intraocular injections. This breakthrough has the potential to revolutionize the management of AMD worldwide and pave the way for similar approaches to other chronic conditions characterized by pathological angiogenesis.

Subject of Research: Animals

Article Title: mRNA vaccination mitigates pathological retinochoroidal neovascularization in animal models

News Publication Date: August 13, 2025

Web References: http://dx.doi.org/10.1016/j.vaccine.2025.127451

Image Credits: Institute of Science Tokyo

Keywords: Health and medicine, Clinical research, RNA, Genetic material, Vaccine development, Macular degeneration, Vision disorders, Amyloidosis, Diseases and disorders, Vaccine research

Rotavirus represents a leading cause of severe diarrheal disease in children worldwide, particularly in low- and middle-income countries. Current oral rotavirus vaccines have demonstrated lower efficacy in these regions, creating a gap in effective preventive healthcare. The novel CC24 vaccine, formulated by the CDC, aims to provide a more reliable alternative that circumvents the limitations of oral vaccinations, offering protection to populations that are most vulnerable.

Dr. Demetre Daskalakis, Director of the CDC’s National Center for Immunization and Respiratory Diseases, emphasizes the potential of this clinical trial as a groundbreaking initiative. It not only tests the safety of the CC24 vaccine but also explores the innovative ‘patch’ technology for vaccine administration. This represents a promising step in vaccinating against rotavirus, extending the reach of effective healthcare to communities where traditional methods have faltered.

The paradigm-shifting technology developed by Micron Biomedical streamlines the process of vaccine delivery. It employs a unique needle-free method that integrates dissolvable microarray compounds to administer vaccines painlessly into the skin’s upper layers. This innovation not only drastically improves the comfort of vaccination but also addresses logistical challenges associated with vaccine transport, primarily in regions lacking reliable cold chain infrastructure.

Micron Biomedical formulates vaccines to be more stable at various temperatures, thereby mitigating the necessity for rigorous cold chain requirements. The compact design of the patch enables individuals to self-administer their vaccines easily with a simple button press. Importantly, this technology produces no sharps waste, promoting safer disposal practices and enhancing public health efforts.

Dr. Christina Rostad, an associate professor specializing in Pediatric Infectious Diseases at Emory University and lead investigator of the trial, notes that despite existing oral vaccines, the efficacy in low- and middle-income countries remains suboptimal. This new trial aims to bolster scientific innovation towards life-saving healthcare solutions, supporting broader and more effective vaccine access not only globally but also within the United States.

The microneedle patch technology is particularly advantageous for populations adverse to needles due to its perceived non-invasive nature compared to traditional injections. This psychological barrier can significantly impact vaccination rates, particularly among children and adults who might forgo vaccinations due to fear of needles. The trial aims to provide critical insights into the viability and acceptability of this groundbreaking delivery method, reinforcing community participation in immunization initiatives.

This clinical trial builds upon previous explorations of Micron Biomedical’s technology, which has shown promise in delivering self-administered seasonal influenza vaccines. Studies have also indicated potential applications in vaccinations for diseases like measles and rubella, illustrating the versatility of this innovative approach to vaccine administration.

Steven Damon, CEO of Micron Biomedical, expresses enthusiasm for collaborating with Emory University and the CDC on this transformative initiative. He underscores that accelerating access to vital vaccines and therapeutics directly influences public health outcomes, particularly during times of epidemic and pandemic, as well as catering to the needs of military and national security applications.

As part of the trial’s goals, this phase I double-blind placebo-controlled study will analyze the safety, immunogenicity, and reactogenicity of the CC24 vaccine when delivered via Micron Biomedical’s microarray technology. The trial will recruit fifty healthy adults aged 18 to 45, with data generated here expected to inform future studies involving pediatric populations, propelling the research forward towards broader applications in children.

In summary, the initiation of this clinical trial heralds a new era in vaccine development characterized by innovative technologies that can transform the landscape of public health. The utilization of dissolvable microarrays not only stands to enhance the delivery of vaccines but also reflects a growing commitment to tackling pressing global health challenges, particularly in regions where traditional vaccine strategies have fallen short.

As this trial progresses, it may redefine how vaccines are perceived and administered, enhancing overall compliance and effectiveness. It also embodies a significant leap towards addressing inequities in healthcare access and ensuring that vulnerable populations receive adequate protection against infectious diseases.

This innovation in vaccine delivery paves the way for further research and development in the field, with the potential to revolutionize how the global health community approaches vaccination programs, ultimately saving countless lives and improving health outcomes worldwide.

Subject of Research: People
Article Title: Emory University and Micron Biomedical Launch Clinical Trial for Novel Rotavirus Vaccine Using Microneedle Patch Technology
News Publication Date: June 16, 2025
Web References: link to clinical trials
References: Lancet Study
Image Credits: Micron Biomedical

Keywords